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Heart disease is the first killer of women in the modern era, regardless of age, race and of ethnicity, although its prevalence rises 
after menopause. Modern women have professional and housewife responsibilities, consume excess of fat and carbohydrates, smoke, 
do not exercise regularly and do not have enough time to rest. This situation leads to overweight, dyslipidemia, arterial hyperten-
sion, impaired glucose tolerance and diabetes. Women do not often participate in preventive studies and still undergo less intensive 
and invasive evaluation and treatment for chest pain when compared to men. However, the rate of coronary death is twice higher 
in women than in men after myocardial infarction and revascularization procedures. The objective of this review is to analyze the 
main gender differences regarding symptoms, diagnosis, management and prognosis of coronary heart disease and to discuss the 
influence of hormonal replacement therapy in the prevention of cardiovascular disease in postmenopausal women. 
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Over several decades there has been a general belief 
that women should not have coronary heart disease and 
exceptionally would experience a heart attack. Nowadays it 
is recognized that this belief it is not true, as heart disease is 
the first killer of women, regardless of race and of ethnicity; 
it also strikes at younger ages than most people think and 
the risk rises in the middle age; mostly, two-thirds of women 
who have heart attacks never fully recover.1 In 2006, 315,000 
American women died from heart disease, in contrast with 
82,000 deaths from stroke and 41,000 from breast cancer.1 
In Brazil, 69,493 people died from myocardial infarction in 
2006, 40.8% of whom were women.2 Women in the modern 
era have many professional responsibilities, in addition to their 
responsibility to take care of their home, children, husband and 
older relatives. On the other hand, more and more women live 
by themselves. In general, women consume an excess of fat and 
carbohydrates, do not exercise regularly and do not have enough 
time to rest. This situation leads to overweight, dyslipidemia, 
arterial hypertension, impaired glucose tolerance and diabetes. 
Most importantly, smoking is increasing among women. It is 
well known that diabetes and smoking are strong predictors of 
coronary events in both genders, but the risk is two to four-fold 
greater in women.3 Diabetes in women is frequently associated 
with myocardial infarction, heart failure and death.3 In the past, 
there was a lack of participation of women in preventive and 
research studies and there is increasing evidence that women 
undergo intensive and invasive evaluation and treatment for 
chest pain much less frequently than men. When acute coronary 
events occur in women, they are generally older, have multiple 
risk factors and coexisting illnesses and the rate of in-hospital 
death is always substantially greater than in men, even after 
revascularization procedures.3 Women and men differ in 
symptoms, diagnostic procedures and prognosis of coronary 
heart disease. These differences will be discussed in this review.
Chest pain in women
Chest pain has consistently been underestimated in 
women because of the disappointing results of evaluations 
of this symptom in the past. In the CASS (Coronary Artery 100
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Surgery Study), 30% of women with typical angina and 64% 
with atypical angina had normal coronary angiograms, but 
this was observed in only 7% and 34% of men, respectively.4 
Syndrome X, which was defined as symptoms and signs 
of myocardial ischemia in the presence normal coronary 
angiograms,5 predominates in women, but this syndrome 
may represent microvascular disease or endothelial 
dysfunction, which are more often observed in women. 
Recently, data from WISE (Women’s Ischemia Syndrome 
Evaluation) and WTH (Women Take Heart) demonstrated 
that rates of cardiovascular events were highest for 
symptomatic women with nonobstructive coronary artery 
disease compared to symptomatic women with normal 
coronary arteries; on the other hand, symptomatic women 
with normal coronary arteries had almost three-fold higher 
rates of events when compared to asymptomatic women.6 
These facts suggest that in women, as in men, chest pain 
compatible with angina deserves careful evaluation.
Silent myocardial ischemia in women
Silent myocardial ischemia, the objective evidence of 
myocardial ischemia in the absence of angina or anginal 
equivalents, is considered more prevalent in men than in 
women. In the ACIP (Asymptomatic Cardiac Ischemia Pilot) 
study the diagnosis of silent ischemia was difficult in women 
because ambulatory electrocardiographic monitoring failed 
to demonstrate ischemia in daily activities, and women with 
positive exercise testing did not have significant obstructive 
coronary lesions at angiography; for this reason, women 
represented only 25% of the studied population.7 Patients 
of both sexes with silent myocardial ischemia usually 
have severe and extensive coronary artery disease8 and 
unfavorable prognosis.9 However, totally asymptomatic 
women are still considered at low risk for coronary disease 
unless they have diabetes or peripheral arterial disease.10
Noninvasive diagnosis of ischemia in women
The standard exercise electrocardiogram testing is the most 
commonly used of the noninvasive tests for the assessment of 
myocardial ischemia. However, electrocardiographic changes 
during exercise are considered of diminished accuracy in 
women (sensitivity of approximately 60%, specificity of 
approximately 70%) due in part to an increased rate of false 
positive results.10 Several factors may influence exercise testing 
responses in women, such as a lower prevalence of coronary 
artery significant lesions; a higher prevalence of single vessel 
disease; microvascular disease and vascular spasms; limited 
exercise tolerance; breast attenuation artifacts; hormonal 
influences mimicking digitalis-like false positive responses. 
Anatomical factors, such as smaller coronary artery size 
and smaller left ventricular chamber size and metabolic and 
hemodynamic influences, such as a lesser increase in the 
left ventricular ejection fraction and an inappropriate release 
of catecholamines.11 Many investigators have attempted to 
improve the diagnostic accuracy of exercise testing in women 
by creating new variables and formulas. One of these is the 
DTS (Duke Treadmill Score), which considers exercise time, 
ST deviation and effort angina; although the DTS has been 
related to the probability of severe coronary disease and 
survival,12 it has not found widespread acceptance in clinical 
practice. The exercise or pharmacological stress-imaging 
methods are now preferred as initial strategies for intermediate 
to high-risk women; however, the exercise electrocardiographic 
test has a high negative predictive value in women at low risk.10
According to the American Heart Association, women are 
considered to be at intermediate or high-risk for coronary heart 
disease if they have typical or atypical angina and are over 50 
years, or are younger than 50 years but have typical angina; 
asymptomatic women at any age are considered of low-risk 
unless they are diabetic or present peripheral artery disease.10 
Myocardial perfusion imaging
Cardiovascular imaging may be obtained by myocardial 
scintigraphy or echocardiography. Perfusion imaging with 
exercise or pharmacological stress has provided important 
information on the risk stratification of men and women; 
however, this technique has some limitations in women due 
to attenuation of myocardial activity caused by the presence 
of the breasts and because of the smaller female heart. 
These problems were mostly encountered with tallium-201 
scintigraphy, but they were almost eliminated with the use 
of 99m-Tc-sestamibi.10 Taillefer et al.13 reported that the 
specificity for coronary lesions of ≥ 70% was 67.2% for 
Tl-201, 84.4% for Tc-99m sestamibi SPECT perfusion 
and 92.2% for Tc-99m sestamibi-gated SPECT. On the 
other hand, both Tl-201 and Tc-99m sestamibi had similar 
sensitivities for the detection of ischemia.13 Santana-Boado 
et al.14 analyzed 702 consecutive men and women (44%) 
submitted to exercise myocardial perfusion imaging using 
Tc-99m-MIBI and reported that that the sensitivity in 
women was significantly lower than in men (85% vs. 93%, 
respectively) but that the specificities were similar (91% 
vs. 96% respectively) for those who underwent coronary 
angiography. After correction for the patients without 
coronary angiography, the sensitivity and specificity were 
not significantly different in men and women and the authors 
suggested that the diagnostic accuracy of Tc-99m-MIBI 
was globally satisfactory.14 Berman et al.15 reported relevant 
prognostic information with adenosine myocardial perfusion 101
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SPECT; they followed 2,656 women and 2,677 men over 
27.0±8.8 months and observed annual rates of cardiac death 
of 5.5% and 7.0%, respectively, in men and women with 
severe abnormal scans. In diabetic patients, the predicted rate 
of cardiac death in diabetic women with severe abnormal 
scans was 8.5%, which is significantly higher than the 6.0% 
predicted mortality for diabetic men with severe imaging 
abnormalities; among non-diabetics, the predicted survival 
was similar in men and women.15 Pharmacological stress 
imaging is indicated in patients with a poor tolerance to 
exercise, such as older women, obese patients, patients with 
a left bundle-branch block and diabetic women.
Stress Echocardiography provides valuable information 
about ventricular function and stress-induced ischemia. 
Exercise echocardiography may be performed via a treadmill 
or supine or upright bicycle exercise; pharmacological 
stress may be performed using a vasodilator (dipyridamole 
or adenosine) or dobutamine-atropine. Marwick et al.16 
compared the results of exercise testing with those of exercise 
echocardiography in women the sensitivities of both tests 
were similar, 77% and 81%, respectively, but the specificity 
and accuracy of exercise echocardiography were significantly 
higher than those of exercise testing, 80% vs. 56% and 81% 
vs. 64%, respectively.16 Similar results were observed when 
exercise testing was compared to high-dose dipyridamole-
echocardiography in women; the sensitivities were similar, 
69% and 77%, respectively, but the specificity and accuracy 
of dipyridamole-echocardiography were significantly higher 
than those of exercise testing, 93% vs. 52% and 87% vs. 59%, 
respectively.17 On the other hand, according to a report from 
Dionisopoulos et al.,18 dobutamine-stress echocardiography 
has demonstrated high sensitivity, specificity and accuracy 
in both men and women: 85%, 96% and 88% and 90%, 79% 
and 86%, respectively, for men and women. Pharmacological 
stress echocardiography with dobutamine seems to provide 
better sensitivity than with dipyridamole; therefore, 
dobutamine is more commonly used.10 Tsutsui et al.19 
reported gender differences in chronotropic and hemodynamic 
responses during dobutamine-atropine echocardiography; 
among patients who were not being treated with beta-blockers 
or calcium channel blockers, the heart rate response was 
higher in women than in men, the test duration was shorter in 
women and the total doses of dobutamine and atropine used 
during the tests were lower in women; no serious adverse 
effects were observed.
Perfusion imaging or echocardiography in women? 
Shaw et al.20 recently compared the prognostic value 
of stress echocardiography versus SPECT imaging. The 
authors analyzed data for 7,397 women submitted to stress 
echocardiography and 13,039 women submitted to SPECT 
imaging and concluded that both methods have a similar 
predictive value of provocative ischemia in estimating 
cardiac death and non-fatal myocardial infarction.20 When 
imaging tests detect ischemia in intermediate to high-risk 
women, coronary angiography is indicated. 
Myocardial infarction in women
Myocardial infarction in women deserves special 
attention because women have worse in-hospital and long-
term prognosis than men. It is generally recognized that 
women have a two-fold higher mortality after myocardial 
infarction compared to men.3 In the pre-thrombolytic era, 
30-day mortality rates up to 28% among women and 16% 
among men were reported and the rates of reinfarction 
were three-fold higher in women than in men.21 The highest 
mortality rates occurred for anterior wall myocardial 
infarction and among the elderly; however, there was a 
consistent 2:1 death ratio when women were compared to 
men.3 Thrombolytic therapy after myocardial infarction 
dramatically reduced mortality rates after myocardial 
infarction, but women still died twice as often as men. The 
Global Utilization of Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronary Arteries (GUSTO-I) 
trial22 analyzed the mortality and clinical and angiographic 
characteristics in 543 women and 1887 men; the unadjusted 
30-day mortality rate after myocardial infarction was 13.1% 
in women, which is significantly higher than the 4.8% rate 
for men. The mortality rate of women with a patent infarct-
related artery was 11.5% versus 3.8% for men, while the 
mortality rate of women with an occluded infarct-related 
artery was 19% versus 5.4% for men; all of these differences 
were significant.22 The women enrolled in GUSTO-I were 
significantly older than the men and had more hypertension, 
diabetes and hypercholesteromia; after adjustment for age 
and clinical and angiographic variables, gender remained an 
independent predictor of 30-day mortality.22 
In 1998, a report of the Third International Study of 
Infarct Survival (ISIS-3) Collaborative Group23 led to 
different conclusions; data obtained from 9,600 women 
and 26,480 men with myocardial infarction reported 35-
day mortality rates of 14.8% and 9.1%, respectively. The 
mortality rate was significantly higher in females; however, 
when women and men were compared within three similarly 
sized groups (<60, 60 to 69, and ≥70 years), the mortality 
rate differences were reduced with decreasing age.23 
Although the early mortality rate was about twice as high 
in women as in men, after the adjustment for age and other 
prognostic factors, gender had at most a small independent 
effect on early mortality after myocardial infarction.23 102
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The following year, Vaccarino et al.24 analyzed data on 
384,878 patients (155,565 women) enrolled in the National 
Registry of Myocardial Infarction (NRMI) between June 
1984 and January 1998; the overall mortality rate during 
hospitalization was 16.7% among women and 11.1% among 
men; the sex-based differences in rates varied according to 
age; among patients less than 50 years of age, the mortality 
rate for women was more than twice that for the men; the 
difference decreased as age increased and was no longer 
significant after the age of 74.24 In 2001, MacIntyre et 
al.25 reported data on all National Health Service hospital 
admissions in Scotland. Among 201,114 patients (87,833 
women) admitted between 1986 and 1995, gender-based 
differences in survival varied according to age, with younger 
women (less than 55 years of age) having a significantly 
higher 30-day mortality rate (6.5%) when compared to 
age-matched men (4.8%); with increasing age, the disparity 
in the 30-day survival was attenuated and even reversed in 
favor of women aged over 75 years.25 
In our Institution, Conti et al.6 analyzed 236 consecutive 
young patients (54 women) with acute myocardial infarction, 
aged from 27 to 45 years, and observed that the reinfarction 
rate was three-fold higher in women than in men during 
hospitalization; the mortality rate did not differ significantly, 
but was higher in women (5.5%) than in men (3.3%). 
Recently, the Acute Myocardial Infarction in Switzerland 
(AMIS) Plus Registry27 analyzed 5,633 women and 14,657 
men with acute coronary syndromes (ACS), 60% with 
ST-segment elevation (STE) myocardial infarction. The 
mortality rate was 13.0% in women with STE-ACS and 
7.5% in women with non-STE-ACS; these rates were 
significantly higher than the respective mortality rates 
in men, 7.2% and 4.9%.27 The gender differences in the 
in-hospital mortality were mostly due to younger age of 
patients: the in-hospital mortality according to age group 
showed that significantly more women than men died only 
among the group aged less than 50 years. These findings 
challenge the general belief that age but not gender is 
responsible for the excess mortality of women after 
myocardial infarction.
Why do young women have unfavorable outcomes after 
myocardial infarction? 
This question remains to be answered, but several 
hypotheses exist.Young women with coronary heart 
disease may be particularly predisposed to have more 
aggressive disease that may override the protective effect 
of estrogens.24 Young women with coronary heart disease 
may have more risk factors, but adjustments for diabetes 
and other risk factors accounted for only about 10% of the 
gender differences in the NRMI. Young women may have 
a hypercoagulable state, coronary spasms or microvascular 
disease; plaque erosions are predominant in young women 
who die suddenly while older women present rupture of 
plaques; also, young women have less coronary narrowing 
than older women and men.24 These and other mechanisms 
may be genetic in nature or have a genetic predisposition. 
The complete explanation of the unfavorable prognosis 
of young women with myocardial infarction is far from 
elucidated.
Myocardial revascularization in women
Coronary artery bypass grafts (CABG) have been 
performed for several decades and have been shown to 
relieve angina and ischemia and prolong survival in selected 
groups, such as patients with left main coronary artery 
disease or three-vessel disease and ventricular dysfunction. 
However, the in-hospital mortality after CABG has always 
been reported as twice as high in women relative to men.3 
This increase has been attributed to anatomical and clinical 
differences: women are generally older; have a smaller body 
size and coronary lumen; and have a higher incidence of 
risk factors, such as diabetes, systemic hypertension3 and 
hypercholesteromia. In 1993, Rahimtoola et al.28 published 
the results of CABG for 1,979 women and 6,927 men: 
the operative mortality was found to be 2.7% for women 
and 1.9% for men; women had a lower long-term survival 
compared to men in a 15 to 18-year follow-up. When all of 
the risk factors and patient characteristics were considered, 
the independent risk factors for poorer survival were older 
age, previous CABG, previous myocardial infarction and 
diabetes, but not gender.28 
In 2002, Vaccarino et al.29 studied 51,187 patients 
(15,178 women) included in the National Cardiovascular 
Network database; in all age groups, women had less severe 
coronary artery disease and higher left ventricular ejection 
when compared to men. In the youngest age category (<50 
years old), the in-hospital mortality rate was three-fold 
higher for women compared to men (3.4% vs. 1.1%); among 
the patients aged 50-69 years, women were 2.4-fold more 
likely to die compared to men (2.6% vs. 1.1%); the gender-
based differences decreased with increasing age.29 These 
findings were similar when gender differences in mortality 
were analyzed after myocardial infarction. More recently, 
Humphries et al.30 reported data from the British Columbia 
Cardiac Registry demonstrating a significant improvement 
in short-term mortality in women undergoing CABG from 
1991 to 2004. The authors analyzed 20,229 men and 4,983 
women and observed that the 30-day mortality decreased 
significantly in men (2.4% to 1.9%) and women (5.6% to 103
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1.9%) over the 14-year study period; overall, the 30-day 
mortality was 2.0% in men and 3.6% in women, and the 
greatest difference was observed in the <50-year-old group.30 
There is no definite explanation for these divergent results. 
Besides the genetic and vascular mechanisms that have been 
discussed above, coronary disease is not very frequent in 
women under 50 years. It is likely that only the most severe 
cases are recognized and receive CABG.29 On the other 
hand, Puskas et al.31 reviewed data for 42,477 consecutive 
patients (11,785 women) submitted to CABG in 63 North 
American centers during a two-year period (2004-2005); on-
pump CABG (ONCAB) was compared to off-pump CABG 
(OPCAB). After an adjustment for preoperative risk factors, 
patients treated with OPCAB had a significantly reduced 
risk of death, stroke, myocardial infarction and other adverse 
outcomes when compared to those treated with ONCAB; 
the benefits were most apparent in women.31 The authors 
concluded that OPCABG reduced the gender disparity in 
clinical outcomes after coronary revascularization.31
Percutaneous coronary interventions in women are 
less successful when compared to men. The National 
Heart Lung and Blood Institute (NHLBI) investigators32 
analyzed the results of percutaneous transluminal coronary 
angioplasty (PTCA) performed during 1985/1986 in 2,136 
patients (546 women); women were older than men, had 
more coronary risk factors and worse anginal symptoms. 
There was no gender difference when successful procedures 
were considered; however, the in-hospital mortality was 
significantly higher in women as compared to men, 2.6% 
and 0.3%, respectively.32 The mortality rate among women 
older than 65 years was 5.6%, which is ten-fold higher 
than that for men.32 These results led some physicians o 
contraindicate angioplasty in women aged 65 or older.33 
Later, another report of the NHLBI experience in 1993/1994 
demonstrated better clinical outcomes including survival 
in women submitted to PTCA, although the women were 
older than those analyzed in 1985/1986 and had multiple 
co-morbidities.34 
A  later  report  from  the  Bypass  Angioplasty 
Revascularization Investigation (BARI) group analyzed 489 
women and 1340 men and showed no gender differences 
in early or late mortality after PTCA and CABG.35 These 
results have not been confirmed by other investigators; Vakili 
et al.36 conducted a retrospective cohort study of all patients 
undergoing primary PTCA for a first acute myocardial 
infarction in New York state in 1995. 1,044 patients (317 
women) were identified; the women were older than the 
men and had significantly more risk factors. The men were 
treated earlier, with a shorter time following symptom onset 
(within 6 hours), compared to women.36 In this analysis, the 
unadjusted in-hospital mortality rate was significantly higher 
in women (7.9%) than in men (2.3%); after adjustment 
for clinical variables and risk factors, women maintained 
a 2.3-fold higher risk of in-hospital death compared to 
men.36 Watanabe et al.37 analyzed data obtained from the 
Nationwide Inpatient Sample in 1997; during the study 
period, 118,548 PTCA were performed and 59% involved 
the placement of stents. Analysis were performed separately 
for patients with and without acute myocardial infarction.37 
Women had a two-fold higher mortality rate than men 
despite the presence of myocardial infarction, this gender 
difference remained significant for patients who underwent 
conventional PTCA or stenting.37 In this study, female 
gender was an independent predictor of death.37 In the recent 
report of the Acute Myocardial Infarction in Switzerland 
(AMIS) Plus Registry,27 the in-hospital mortality of women 
who underwent percutaneous coronary intervention was 
significantly higher than that of men (4.2% vs. 3.0%, 
respectively); the trend of higher mortality was observed 
among women younger than 50 years. In summary, women 
still have a worse prognosis than men when submitted to 
myocardial revascularization procedures.
Why are there gender differences in coronary heart 
disease outcomes?
This question also remains to be answered. Women 
may differ from men in several aspects: a) at the molecular 
level, sex-gene related diseases may occur; b) physiological 
differences may exist due to sex-hormones and to different 
responses to risk factors causing different patterns of 
illness; c) different responses to pharmacological agents 
may occur, due to pharmacokinetic differences, e.g. a 
different metabolization rates, side-effects and risks; d) the 
level of disability may be mediated by sex-specific disease 
expression. Coronary heart disease in women deserves 
further investigation and is a challenge that should be faced 
in the 21st century.
Hormonal replacement therapy and cardiovascular risk
Previous observational epidemiological studies have 
suggested that hormone replacement therapy could reduce 
morbidity and mortality from coronary heart disease 
in women after menopause; however, the incidence of 
endometrial cancer, breast cancer, stroke and venous 
thromboembolism could be increased.38 In 1995, the 
Postmenopausal Estrogen/Progestin Interventions (PEPI) 
trial enrolled 875 healthy postmenopausal women aged 45 
to 64 years who had no known contraindication to hormone 
therapy.39 The participants were randomly assigned in equal 
numbers to the following groups: 1) placebo; 2) conjugated 104
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equine estrogen (CEE), 0.625 mg/d; 3) CEE, 0.625 mg/d 
plus cyclic medroxyprogesterone acetate (MPA), 10 mg/d 
for 12 d/mo; 4) CEE, 0.625 mg/d plus consecutive MPA, 
2.5 mg/d; or 5) CEE, 0.625 mg/d plus cyclic micronized 
progesterone (MP), 200 mg/d for 12 d/mo.39 After a 
3-year follow up, estrogen alone or in combination with a 
progestin improved lipoprotein levels (increased HDL-C 
and decreased LDL-C) and lowered fibrinogen plasma levels 
without detectable effects on the post-challenge insulin 
level or blood pressure.39 In women with a uterus, CEE 
plus cyclic MP had the most favorable effect on HDL-C 
and was associated with no excess risk of endometrial 
hyperplasia.39 After publication of the beneficial results 
of PEPI, the Heart and Estrogen/progestin Replacement 
Study (HERS),40 a randomized clinical trial, was conducted 
briefly, 2,763 postmenopausal women younger than 80 years 
(mean age 66.7 years) with established coronary disease 
who had not had a hysterectomy were enrolled. The women 
were randomly assigned to the placebo or CEE+MPA daily 
group; after a 4-year follow-up, the hormone replacement 
therapy did not reduce coronary events, but increased the 
rate of thromboembolism and gall bladder disease.40 Based 
on these findings, hormone replacement therapy was not 
recommended for secondary prevention of coronary heart 
disease. The results were disappointing. The HERS was 
criticized because the enrolled women were old and had 
previous coronary disease. A subsequent study, the Women’s 
Health Initiative (WHI),41,42 was conducted involving 27,347 
postmenopausal women who were to be followed for eight 
to nine years; the women were aged 50 to 79 years, with 
(±10%) and without coronary disease, with a uterus or with 
a prior hysterectomy. The first arm of WHI enrolled 16,608 
postmenopausal women with a uterus, with (minority) and 
without coronary disease and a mean age of 63.2 years; they 
were randomly assigned to the placebo or CEE+MPA daily 
group; after a mean of 5.2  years of follow-up, the study 
was interrupted because hormone therapy was associated 
with a 29% increase in coronary events, 26% increase in 
breast cancer, 41% increase in stroke and a twofold increase 
in thromboembolism.41 The second arm of WHI enrolled 
10,739 postmenopausal women with prior hysterectomy, 
with (minority) and without coronary disease and a mean 
age of 63.6 years; they were randomly assigned to the 
placebo or CEE+MPA group.42 After a mean of 6,8  years 
of follow-up, the study was interrupted because hormone 
therapy was associated with a 39% increase of stroke; 
notably the risk of coronary events was not affected.42 
The disappointing results of WHI led the investigators to 
a secondary analysis of their data; they studied hormone 
therapy and the risk of cardiovascular disease by age and 
years after menopause.43 The analysis of this study was 
based on combined data from the two trials: separate tests 
for trends were performed to examine differences in the 
hormone effects across three preselected, coded categories 
of age (50-59, 60-69, 70-79 years) or years since menopause 
(<10, 10-19, ≥20).43 The numbers of events increased with 
increasing age; there were no significant increases in risks 
due to hormone therapy for coronary disease and death at 
ages 50 to 59 years, although the risk of stroke was increased 
at all ages.43 The risk of coronary events and death did not 
increase in women that initiated hormone therapy with less 
than 10 years since menopause, but increased significantly 
in women with 20 or more years after menopause.43 The risk 
of stroke was increased at any time.43 The WHI investigators 
concluded that hormone therapy could be used short-term 
for the relief of moderate to severe vasomotor symptoms, 
but not to prevent cardiovascular disease.43 At present, the 
American Heart Association44 and the European Society of 
Cardiology45 agree that hormone replacement therapy cannot 
be recommended for the prevention of cardiovascular disease 
in postmenopausal women.
In conclusion, women do have coronary heart disease 
and die twice as often as men after myocardial infarction 
and  myocardial  revascularization  procedures.  The 
recommendations for prevention of mortality consist of 
major traditional risk factor interventions addressing blood 
pressure, glucose and lipid plasma levels and lifestyle 
interventions, including smoking cessation, increased physical 
activity and weight control. Hormone replacement therapy is 
contraindicated for the prevention of cardiovascular disease in 
postmenopausal women. Women deserve careful evaluation 
for coronary symptoms even though some diagnostic methods 
are less accurate in women than in men. Women are less 
frequently treated for coronary disease as compared to men. 
We hope that such gender differences in the management of 
coronary disease will decrease in the 21st century.
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